Negative allosteric modulation of CB1 cannabinoid receptor signalling decreases intravenous morphine self-administration and relapse in mice

被引:3
作者
Oliva, Idaira [1 ]
Kazi, Fezaan [1 ]
Cantwell, Lucas N. [2 ]
Thakur, Ganesh A. [2 ]
Crystal, Jonathon D. [1 ]
Hohmann, Andrea G. [1 ,3 ]
机构
[1] Indiana Univ Bloomington, Dept Psychol & Brain Sci, Bloomington, IN USA
[2] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA USA
[3] Indiana Univ Bloomington, Gill Inst Neurosci, Bloomington, IN USA
基金
美国国家卫生研究院;
关键词
cannabinoid receptor 1; morphine; motivation; negative allosteric modulator; opioids; reinforcement; self-administration; ENDOCANNABINOID SYSTEM; REWARD;
D O I
10.1111/adb.13429
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The endocannabinoid system interacts with the reward system to modulate responsiveness to natural reinforcers, as well as drugs of abuse. Previous preclinical studies suggested that direct blockade of CB1 cannabinoid receptors (CB1R) could be leveraged as a potential pharmacological approach to treat substance use disorder, but this strategy failed during clinical trials due to severe psychiatric side effects. Alternative strategies have emerged to circumvent the side effects of direct CB1 binding through the development of allosteric modulators. We hypothesized that negative allosteric modulation of CB1R signalling would reduce the reinforcing properties of morphine and decrease behaviours associated with opioid misuse. By employing intravenous self-administration in mice, we studied the effects of GAT358, a functionally-biased CB1R negative allosteric modulator (NAM), on morphine intake, relapse-like behaviour and motivation to work for morphine infusions. GAT358 reduced morphine infusion intake during the maintenance phase of morphine self-administration under a fixed ratio 1 schedule of reinforcement. GAT358 also decreased morphine-seeking behaviour after forced abstinence. Moreover, GAT358 dose dependently decreased the motivation to obtain morphine infusions under a progressive ratio schedule of reinforcement. Strikingly, GAT358 did not affect the motivation to work for food rewards in an identical progressive ratio task, suggesting that the effect of GAT358 in decreasing opioid self-administration was reward specific. Furthermore, GAT58 did not produce motor ataxia in the rotarod test. Our results suggest that CB1R NAMs reduced the reinforcing properties of morphine and could represent a viable therapeutic route to safely decrease misuse of opioids. CB1R negative allosteric modulator (NAM) GAT358 inhibits morphine-addicted behaviours. Specifically, GAT358 reduced intravenous morphine infusion consumption, decreased morphine relapse-like behaviour and lowered the motivation to work to obtain morphine infusions without producing side effects like motor ataxia or anhedonia.image
引用
收藏
页数:11
相关论文
共 27 条
[1]   CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity [J].
Baillie, Gemma L. ;
Horswill, James G. ;
Anavi-Goffer, Sharon ;
Reggio, Patricia H. ;
Bolognini, Daniele ;
Abood, Mary E. ;
McAllister, Sean ;
Strange, Phillip G. ;
Stephens, Gary J. ;
Pertwee, Roger G. ;
Ross, Ruth A. .
MOLECULAR PHARMACOLOGY, 2013, 83 (02) :322-338
[2]   Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies [J].
Befort, Katia .
FRONTIERS IN PHARMACOLOGY, 2015, 6
[3]   Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking [J].
Bossert, Jennifer M. ;
Gray, Sarah M. ;
Lu, Lin ;
Shaham, Yavin .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (10) :2197-2209
[4]   Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action [J].
Cawston, Erin E. ;
Redmond, William J. ;
Breen, Courtney M. ;
Grimsey, Natasha L. ;
Connor, Mark ;
Glass, Michelle .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (04) :893-907
[5]  
Chang HY, 2018, BMC MED, V16, DOI [10.1186/s12916-018-1058-y, 10.1186/S12916-018-1058-y]
[6]   PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats [J].
Horswill, J. G. ;
Bali, U. ;
Shaaban, S. ;
Keily, J. F. ;
Jeevaratnam, P. ;
Babbs, A. J. ;
Reynet, C. ;
In, P. Wong Kai .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (05) :805-814
[7]  
Iyer V, 2024, bioRxiv, DOI [10.1101/2024.01.06.574477, 10.1101/2024.01.06.574477, DOI 10.1101/2024.01.06.574477]
[8]   Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward [J].
Iyer, Vishakh ;
Rangel-Barajas, Claudia ;
Woodward, Taylor J. ;
Kulkarni, Abhijit ;
Cantwell, Lucas ;
Crystal, Jonathon D. ;
Mackie, Ken ;
Rebec, George V. ;
Thakur, Ganesh A. ;
Hohmann, Andrea G. .
PHARMACOLOGICAL RESEARCH, 2022, 185
[9]   Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats [J].
Jing, Li ;
Qiu, Yanyan ;
Zhang, Yanan ;
Li, Jun-Xu .
DRUG AND ALCOHOL DEPENDENCE, 2014, 143 :251-256
[10]   Medication-assisted treatment for opioid use disorder [J].
Kaplan, Louise .
NURSE PRACTITIONER, 2019, 44 (03) :10-12